Baudax Bio, Inc.
BXRX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | -100% | 314.3% | -104.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $5 |
| Gross Profit | -$0 | -$0 | -$0 | -$4 |
| % Margin | – | -246.7% | 2,992.9% | -1,445.8% |
| R&D Expenses | $2 | $2 | $3 | $1 |
| G&A Expenses | $4 | $2 | $0 | $0 |
| SG&A Expenses | $4 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$3 | $0 |
| Operating Expenses | $6 | $4 | $5 | $3 |
| Operating Income | -$2 | -$7 | -$5 | -$9 |
| % Margin | – | -23,483.3% | 33,485.7% | -2,774.2% |
| Other Income/Exp. Net | $0 | -$3 | -$3 | -$2 |
| Pre-Tax Income | -$2 | -$7 | -$7 | -$9 |
| Tax Expense | $0 | $3 | $0 | $0 |
| Net Income | -$2 | -$7 | $11 | -$9 |
| % Margin | – | -24,583.3% | -81,457.1% | -2,983.5% |
| EPS | -0.24 | -1.51 | 4.91 | -5.7 |
| % Growth | 84.1% | -130.8% | 186.1% | – |
| EPS Diluted | -0.24 | -1.51 | 4.91 | -5.7 |
| Weighted Avg Shares Out | 8 | 5 | 2 | 2 |
| Weighted Avg Shares Out Dil | 8 | 5 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $2 |
| EBITDA | -$0 | -$0 | -$24 | -$7 |
| % Margin | – | -246.7% | 169,150% | -2,157.7% |